BioBridgeX
Log inCompare quotes
Indication

Dermatology CRO and CDMO vendors

Free for buyersNeutral marketplace
Quick answer

Outsourcing a dermatology program means sourcing CRO and CDMO partners for topical and systemic work: skin disease models (psoriasis, atopic dermatitis, acne, wound healing), dermatopharmacokinetics and in vitro permeation, photosafety and dermal toxicology, semisolid and patch formulation, and clinical trials scored on PASI, EASI, and IGA. BioBridgeX is a neutral marketplace, free for buyers, that lets you compare qualified suppliers and contract once.

Dermatology CRO and CDMO vendors on BioBridgeX

We are qualifying and publishing Dermatology CRO and CDMO vendors now. Tell us what you need and we will match you with vetted vendors, or list your organization to be among the first.

What kind of CRO work does a Dermatology program need?

Dermatology splits cleanly into two worlds that need different suppliers, and the first thing to decide is which one you are in. A topical or transdermal program lives or dies on whether the drug crosses the stratum corneum and reaches the right layer of skin, so the centre of gravity is dermatopharmacokinetics, permeation work, and semisolid formulation. A systemic dermatology program (an oral JAK inhibitor for atopic dermatitis, a biologic for psoriasis or hidradenitis) looks much more like a conventional immunology or small-molecule program, with standard PK, tox, and clinical operations, plus the disease-specific endpoints. A supplier that is excellent at one is often a beginner at the other.

On the discovery and preclinical side, the indication-specific piece is the model. Psoriasis work usually runs through the imiquimod-induced mouse model with epidermal thickness and cytokine readouts; atopic dermatitis through oxazolone or DNFB sensitization or filaggrin-relevant models; acne, wound healing, and fibrosis each have their own established systems. Ask whether the CRO already has the specific model validated in-house with historical control data, because spinning one up for the first time on your program is slow and noisy. Human skin explants and reconstructed-epidermis tissues sit alongside the in vivo models for barrier, irritation, and early efficacy work.

The part that genuinely separates dermatology CROs from generalists is skin penetration and dermal safety science. In vitro permeation testing in Franz cells on human skin, in vitro release testing for semisolids, and tape-stripping dermatopharmacokinetics are specialist assays with real method-development demands, and for a topical generic the Q3 microstructure and IVPT package is the heart of the filing. Photosafety (3T3 NRU phototoxicity and in vivo photoallergy) matters because skin drugs get sun exposure. None of this is exotic, but it is a distinct skill set, and it is where a cheap, non-specialist lab quietly costs you a repeated study.

  • Discovery and disease modeling: human skin explants, 3D reconstructed epidermis (EpiDerm, EpiSkin) for irritation and barrier work, and in vivo models such as imiquimod-induced psoriasis, oxazolone or DNFB atopic dermatitis, and excisional or diabetic wound-healing models with histology and immunohistochemistry readouts.
  • Dermatopharmacokinetics and skin penetration: in vitro permeation testing (IVPT) on human cadaver skin in Franz cells, in vitro release testing (IVRT) for semisolids, tape-stripping dermatopharmacokinetics, and skin-distribution work that shows how much drug actually reaches the target layer.
  • Topical and transdermal toxicology: dermal irritation and sensitization (LLNA or the in vitro defined-approach battery), photosafety (3T3 phototoxicity, in vivo photoallergy), dermal repeat-dose tox, and patch or transdermal application studies that small-molecule generalist labs are not always set up to run.
  • Formulation and CDMO supply: semisolid creams, ointments, gels, lotions, foams, and transdermal patches, plus rheology, globule-size and microstructure characterization (Q3 sameness for topical generics), and GMP clinical supply of the finished topical product.
  • Clinical operations with derm-specific expertise: investigators and sites that recruit psoriasis, atopic dermatitis, acne, vitiligo, hidradenitis, or alopecia patients, trained graders for the validated scores, and central reads of standardized photography.

How do you choose a CRO for Dermatology?

Start with fit, not the size of the logo or the headline rate. The single most common mistake in dermatology sourcing is handing a topical penetration program to a strong general small-molecule lab that has never run an IVPT study on human skin, or routing a systemic biologic through a topical specialist. Decide your route of administration and filing pathway first, then filter suppliers against that, because the assay menu, the models, and the regulatory expectations all change completely between a cream and an oral.

For clinical work, the binding constraint is almost always patient access and grading consistency, not study conduct in the abstract. Atopic dermatitis, hidradenitis suppurativa, vitiligo, and alopecia areata each have their own recruitment realities, and a CRO that fills oncology Phase 3 sites fast can stall on a thinly spread derm Phase 2. Ask who the named investigators are, how graders are trained and re-calibrated on the validated scores, and whether photography is centrally read. A score that drifts between sites quietly destroys the statistics you are paying for.

Use the same discipline you would on any outsourcing decision: score two or three suppliers against one written scope rather than collecting quotes that measure different things. The cheapest topical study you cannot file, or cannot reconcile, is the most expensive outcome there is, and in dermatology that failure mode usually shows up as a permeation or sameness package a reviewer does not accept.

  • Therapeutic-area experience that matches your route: confirm the team has run topical and transdermal programs (IVPT, IVRT, dermatopharmacokinetics) if you are topical, or genuine systemic derm clinical experience if you are oral or biologic. The two are not interchangeable.
  • Relevant disease models and method validation: ask which skin models are already running in-house with historical control data (imiquimod psoriasis, oxazolone atopic dermatitis, wound healing), and whether their IVPT and permeation methods already detect your compound in the skin layer that matters.
  • Patient access and grading quality for clinical work: derm trials hinge on site recruitment in the specific indication and on trained, consistent graders for PASI, EASI, IGA, or the acne lesion counts, plus standardized photography with central reads to control inter-rater drift.
  • Regulatory track record for your filing type: a 505(b)(2) or topical generic (ANDA) program leans on IVRT, IVPT, and Q1/Q2/Q3 sameness aligned to FDA product-specific guidance, while a novel biologic needs a clean GLP and GCP inspection history. Match the supplier to the pathway.
  • Data quality and reporting honesty: clean dermatopharmacokinetic datasets, straight reporting of failed runs and out-of-spec results, validated bioanalytical methods at the sensitivity a low-dose topical needs, and auditable histopathology with a named pathologist.
  • Capacity, turnaround, and change-order terms: Franz-cell and skin-source availability, report turnaround (not just bench time), and how they price a change order when a cohort fails or a protocol amends, because that is where topical budgets drift.

Frequently asked questions

What animal and in vitro models are used in dermatology research?
It depends on the indication. Psoriasis work most often runs through the imiquimod-induced mouse model with epidermal thickness and inflammatory cytokine readouts. Atopic dermatitis commonly uses oxazolone or DNFB sensitization models. Acne, wound healing, fibrosis, and pigmentation each have their own established systems. Alongside the in vivo models, human skin explants and 3D reconstructed epidermis (such as EpiDerm or EpiSkin) cover barrier, irritation, and early efficacy questions without an animal. The practical advice is to ask whether the CRO already has your specific model validated in-house with historical control data, rather than building it for the first time on your dollar.
Does a dermatology drug need photosafety testing?
Usually yes, because skin-applied and many systemic dermatology drugs reach sun-exposed tissue. The common package is an in vitro 3T3 NRU phototoxicity assay as a first screen, followed where indicated by in vivo phototoxicity and photoallergy work, run against ICH S10 guidance on photosafety evaluation. Compounds that absorb light in the relevant range, distribute to skin or eye, or are applied topically are the ones that trigger the assessment. Confirm with the CRO whether a given study is exploratory or regulatory-grade, since paying GLP prices for an early screen, or filing an exploratory result a reviewer expects in GLP, are both avoidable mistakes.
How are dermatology clinical trial endpoints measured?
Most derm trials are scored on validated clinician-rated scales: PASI and IGA for psoriasis, EASI and IGA for atopic dermatitis, lesion counts and IGA for acne, plus indication-specific tools for vitiligo, alopecia, and hidradenitis. Patient-reported measures (DLQI, itch NRS) usually run alongside. Because these scores are visual and subjective, inter-rater and intra-rater drift directly inflates variance and can wash out a real treatment effect. That is why grader training, re-calibration, and central reads of standardized photography are not administrative niceties. They protect the statistical power you are paying a CRO to deliver, so weight a supplier's grading and imaging discipline heavily when you choose.
What is different about developing a topical generic versus a novel dermatology drug?
Quite different in where the work concentrates. A topical generic (ANDA) leans on demonstrating sameness to the reference product: Q1 and Q2 (same components and concentrations), Q3 microstructure and physical characterization, IVRT, and often an IVPT or a comparative clinical endpoint study, all aligned to FDA product-specific guidance for that drug. A 505(b)(2) sits between, reusing some reference data while adding bridging studies. A novel dermatology drug runs the full discovery-through-clinical path with its own efficacy and safety package. Match the CRO to the pathway, because the regulatory expectations and the critical-path studies are not the same, and a lab fluent in one is not automatically fluent in the others.
Do I need separate suppliers for skin penetration, formulation, and clinical work?
Often yes, because the best specialists rarely cover all three equally well. A typical topical program might use a skin-model and dermatopharmacokinetics CRO for permeation and IVPT, a semisolid CDMO for the cream or gel and its GMP clinical supply, and a clinical CRO with real derm site access for the trial. Contracting and paying each one separately is the friction. Through BioBridgeX you can source and compare multiple dermatology suppliers in one place and contract directly with the ones you choose, with BioBridgeX acting as the neutral marketplace.
How does sourcing dermatology CRO and CDMO services through BioBridgeX work?
BioBridgeX is a neutral marketplace, not a lab, so it has no incentive to steer your permeation work or clinical study toward a preferred site. You describe the work (route, indication, the specific services, and timeline) and get matched with qualified dermatology CRO and CDMO suppliers, then compare them on capability, relevant experience, and transparent quotes in one view. A derm program often pulls in several suppliers, a skin-model CRO, a dermatopharmacokinetics lab, a semisolid CDMO, and a clinical CRO, and BioBridgeX lets you compare them and contract directly with each supplier you choose, all in one place. It is free for buyers, suppliers pay a flat 2% fee, and coverage spans every indication and modality, so the same account carries forward as your program advances.

Source Dermatology work with one contract

Compare transparent quotes from qualified Dermatology CRO and CDMO vendors, then contract once. Free for buyers.

Compare quotes